Germany

BioNTech SE

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

China Gives the Go-Ahead for Human Trials of BioNTech's COVID Vaccine Candidate

Lead Product(s): mRNA vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Shanghai Fosun Pharmaceutical

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 16, 2020

Details:

The potential vaccine is one of the two most advanced candidates that BioNTech is working on with its partner Pfizer Inc and they received “fast track” status this week from the U.S. Food and Drug Administration which is designed to speed up the regulatory review process.

BioNTech SE

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

European Investment Bank to provide BioNTech with up to €100 M in debt financing for COVID-19 vaccine development and manufacturing

Lead Product(s): BNT162

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: European Investment Bank

Deal Size: $112.3 million Upfront Cash: Undisclosed

Deal Type: Financing June 11, 2020

Details:

EIB debt instrument will support BioNTech’s global development of BNT162 for prevention of COVID-19 infection as well as scale-up of manufacturing capacity in Europe as part of the company’s global development and supply strategy.

BioNTech SE

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany

Lead Product(s): BNT162

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 29, 2020

Details:

First clinical trial of a COVID-19 vaccine candidate in Germany. Pfizer and BioNTech plan to initiate trials for BNT162 in the United States upon regulatory approval, which is expected shortly.

BioNTech SE

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Biontech And Pfizer to Commence First Clinical Trial of Covid-19 Vaccine Candidates

Lead Product(s): BNT162

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 22, 2020

Details:

BioNTech and Pfizer are jointly developing BNT162. The trial is the first clinical trial of a COVID-19 vaccine candidate to start in Germany, and is part of a global development program.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

BioNTech SE

China Gives the Go-Ahead for Human Trials of BioNTech's COVID Vaccine Candidate

BioNTech SE

European Investment Bank to provide BioNTech with up to €100 M in debt financing for COVID-19 vaccine development and manufacturing

BioNTech SE

BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany

BioNTech SE

Biontech And Pfizer to Commence First Clinical Trial of Covid-19 Vaccine Candidates